Drug Trial Radar · NCT06048588
YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
144
Actual
Start
Oct 8, 2023
Primary completion
Apr 27, 2025
Study completion Apr 27, 2025
Sponsor
- Lead sponsor
- Beijing Inno Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study consists of two parts. The SAD and MAD of part I are a randomized, double-blind, placebo-controlled, single and multiple ascending dose study in healthy adult subjects. The MAD expansion cohort of part I is single arm and multipal ascending dose in heallthy subjects. Part II (phase Ib/IIa) is a multicenter, randomized, controlled, open label, multiple ascending dose study in patients with coronary atherosclerosis.
Conditions
- Atherosclerotic Cardiovascular Disease
Interventions
YN001Drug
In single ascending dose (SAD) part of study in health subjects, YN001 will be administrated one time with dosage from 10 mg to 120 mg (planned). In multiple ascending doses (MAD) part of study in health subjects, YN001 will be given twice a week from 5 mg to 40 mg up to 15 days. In MAD part of study in patients with coronary atherosclerosis, YN001 will be injected weekly or twice a week from 5mg to 40mg up to 85 days.
Placebo for YN001Drug
The injection solution to mimic the YN001
rosuvastatin calcium tabletsDrug
In MAD part of study in patients with coronary atherosclerosis, Rosuvastatin calcium tablets will be taken orally by 10 mg daily up to 85 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part I: The safety and tolerability of YN001 in healthy subjects.Time frame: Up to 29 days
- Part I: Maximum plasma concentration(Cmax) of YN001Time frame: Up to 168 hours of post initiation of last dose
- Part I: Time of maximum concentration (Tmax) of YN001Time frame: Up to 168 hours of post initiation of last dose
- Part I: Elimination half-life (t1/2) of YN001Time frame: Up to 168 hours of post initiation of last dose
- Part I: Area under the plasma concentration-time curve from time 0 to the collection time point of the last measurable concentration (AUC0-t) of YN001Time frame: Up to 168 hours of post initiation of last dose
- Part II: The safety and tolerability of intravenously administered YN001 in patients with coronary atherosclerosis.Time frame: Up to 29 days
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Peking University first hospital
Beijing, Beijing Municipality, China
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
First Hospital of Jilin University
Changchun, Jilin, China
Renji Hospital Shanghai Jiaotong Unv. school of Medicine
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.